InnoLet®, which was developed and is marketed by Novo Nordisk, was approved by the U.S. Food and Drug Administration (FDA) in December 2001 and is now available in pharmacies nationwide.
"The complicated nature of handling and accurately dosing with a vial and syringe, as well as incorrect administration and injection techniques, are among the factors that impact the ability of people with diabetes to correctly self-administer insulin," said Dr. Sherwyn Schwartz, endocrinologist of the Diabetes & Glandular Disease Clinic, San Antonio, Texas. "InnoLet® was designed with patients to overcome these barriers and features a number of innovations that make the device easy to read, hold and use," added Dr. Schwartz.
The dosing dial of InnoLet® -- which resembles a kitchen timer -- has large, easy-to-read numbers in one-unit increments and clicks audibly at each dosage level, making it easier to help select the correct dose.
The unique, reversible dose mechanism of the device allows patients to easily correct a misdialed dose without wasting insulin. In addition, the individual cannot set the dial to a dosage greater than the quantity of insulin remaining in the cartridge, thereby preventing under-dosing. InnoLet® is designed to rest securely against the skin, to help minimize tremor or movement at the needle tip, and to help prevent the person from injecting too deeply.
"I believe
Contact: Andrea Levin
alevin@porternovelli.com
212-601-8337
Porter Novelli
3-Sep-2002